Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Long-Term Debt Repayments (2016)

United Therapeutics' Long-Term Debt Repayments history spans 2 years, with the latest figure at $900000.0 for Q3 2016.

  • For Q3 2016, Long-Term Debt Repayments fell 67.86% year-over-year to $900000.0; the TTM value through Dec 2016 reached $8.8 million, down 93.39%, while the annual FY2016 figure was $8.8 million, 93.39% down from the prior year.
  • Long-Term Debt Repayments for Q3 2016 was $900000.0 at United Therapeutics, down from $7.8 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $90.3 million in Q2 2015 and bottomed at $100000.0 in Q1 2016.